Neurogene Inc. Short-term Investments
Neurogene Inc. (NGNE) had Short-term Investments of $112.91 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:ShortTermInvestments · last filed 2026-08-11
- 2026-06-30: Short-term Investments $112.91M.
- 2026-03-31: Short-term Investments $119.02M.
- 2025-12-31: Short-term Investments $165.17M.
- 2025-09-30: Short-term Investments $194.41M.
| Period end | Short-term Investments | Short-term Investments as first filed |
|---|---|---|
| 2026-06-30 | $112.91M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $119.02M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $165.17M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $194.41M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $215.71M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $221.83M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $175.82M 10-K · filed 2026-03-24 | |
| 2024-09-30 | $72.36M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $42.87M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $19.39M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $48.95M 10-K · filed 2025-03-24 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-18 | $58.50M 10-K · filed 2023-03-20 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-20 | |
| 2014-09-30 | $24.13M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $17.99M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $2.71M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $2.82M 10-Q · filed 2014-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |